Evidence map›Paper›PMID 22286199›Full record

ReviewBlood2012

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Roland B Walter, Frederick R Appelbaum, Elihu H Estey, Irwin D Bernstein

Open access · bronzeAbstract readEvaluation StudyReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 1 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 1 synthesis or guideline pooled it, 317 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in PediatricJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Recent advances in CAR T and CAR NK cell therapy for AML.International journal of hematology · 2026
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Roland B WalterClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. rwalter@fhcrc.org
Frederick R Appelbaum
Elihu H Estey
Irwin D Bernstein
Fred Hutch Cancer Center · USUniversity of Washington · US

Funding

COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
NCI NIH HHS P30 CA015704NCI NIH HHS P30-CA015704-35S6NCI NIH HHS U10 CA098543NCI NIH HHS U10-CA098543
6 · The paper itself

Abstract

Although the identification of cancer stem cells as therapeutic targets is now actively being pursued in many human malignancies, the leukemic stem cells in acute myeloid leukemia (AML) are a paradigm of such a strategy. Heterogeneity of these cells was suggested by clonal analyses indicating the existence of both leukemias resulting from transformed multipotent CD33(-) stem cells as well others arising from, or predominantly involving, committed CD33(+) myeloid precursors. The latter leukemias, which may be associated with an intrinsically better prognosis, offer a particularly attractive target for stem cell-directed therapies. Targeting the CD33 differentiation antigen with gemtuzumab ozogamicin was the first attempt of such an approach. Emerging clinical data indicate that gemtuzumab ozogamicin is efficacious not only for acute promyelocytic leukemia but, in combination with conventional chemotherapy, also for other favorable- and intermediate-risk AMLs, providing the first proof-of-principle evidence for the validity of this strategy. Herein, we review studies on the nature of stem cells in AML, discuss clinical data on the effectiveness of CD33-directed therapy, and consider the mechanistic basis for success and failure in various AML subsets.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticClinical Trials as TopicHumansImmunotherapyLeukemia, Myeloid, AcuteModels, BiologicalMolecular Targeted TherapyNeoplastic Stem CellsSialic Acid Binding Ig-like Lectin 3Treatment OutcomeAntigens, CDAntigens, Differentiation, MyelomonocyticCD33 protein, humanSialic Acid Binding Ig-like Lectin 3

Identifiers

PMID22286199
PMCPMC3383202
OpenAlexW2160026729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.